Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Neoplasms 17Breast Neoplasms 10Carcinoma, Non-Small-Cell Lung 9Neoplasm Metastasis 6Prostatic Neoplasms 5Melanoma 5Lung Neoplasms 5Solid Tumor 3Pain, Postoperative 3Lymphoma, Non-Hodgkin 3Lymphoma 3Leukemia, Myeloid, Acute 3Gastrointestinal Stromal Tumors 3Colorectal Neoplasms 3Anxiety Disorders 3Recurrence 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Pain 2Glioma 2Colonic Neoplasms 2Choledocholithiasis 2Choledochal Cyst 2Carcinoma 2Advanced Solid Tumor 2Advanced Malignancies 2cMET-dysregulated Advanced Solid Tumors 1Urothelial Cancer 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1

Interventions

Cyclophosphamide 346Cytarabine 282fludarabine phosphate 203Methotrexate 186Filgrastim 159Busulfan 148Etoposide 135Peripheral Blood Stem Cell Transplantation 134fludarabine 128Rituximab 119Radiotherapy 111Vincristine 102Cyclosporine 98Daunorubicin 96Antilymphocyte Serum 94Dexamethasone 91Tacrolimus 86Mycophenolic Acid 86Whole-Body Irradiation 81Melphalan 79Imatinib Mesylate 69Idarubicin 67Mercaptopurine 66Granulocyte Colony-Stimulating Factor 66Azacitidine 65Methylprednisolone 59Prednisone 58Doxorubicin 58Clofarabine 54sargramostim 53

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia × Midazolam × Clear all
NCT04067336 2026-05-13

First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia

Kura Oncology, Inc.

Phase 1/2 Active not recruiting
263 enrolled 1 FDA
LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡